ArticleTranslational cancer research2025
A comparison of hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: a bioinformatics analysis.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The genetic and epigenetic differences between hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) and hepatitis C virus-related hepatocellular carcinoma (HCV-HCC) remain underexplored. This study aimed to elucidate DNA methylation patterns and features of HBV-HCC and HCV-HCC through use of an innovative method from a comparative perspective. Methods: We conducted gene expression and methylation analyses to identify differentially expressed genes (DEGs) and differentially methylated probes (DMPs) based on The Cancer Genome Atlas (TCGA) database. Cox survival analysis was employed to identify prognosis-related DEGs (Pro-DEGs). A novel sequential least absolute shrinkage and selection operator (Seq-Lasso) technique was used to integrate gene expression and DNA methylation data, subsequently generating gene-level DNA methylation summaries. These summaries were used to select methylation-expression quantitative trait loci (methyl-eQTLs) from Pro-DEGs for HBV-HCC and HCV-HCC, respectively. Results: Hypomethylation was more prevalent in HBV-HCC than in HCV-HCC in regardless of the genome region. Notably, open sea regions of the HBV-HCC patient group contained the most functionally significant methylation sites, whereas in the HCV-HCC patient group, the most functionally important cytosine-phosphate-guanine (CpG) sites were typically located in shelf regions when positively associated with gene expression within genes. We further constructed and validated a prognostic index (PI) based on six methyl-eQTLs associated with HCC prognosis. Conclusions: Our study found that CpG island sites had the least functional importance in both HBV-HCC and HCV-HCC. And, we also constructed and validated a PI based on six methyl-eQTLs that may be related to HCC prognosis via RFC3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.